AZD2906
Based on 1 publication(s) in Google Scholar
AZD2906 is a selective glucocorticoid receptor (GR) agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.90%
- CAS No.: 1034148-15-6
- 화학식: C26H25FN4O3
- 분자량:460.50
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-120012
Mizacorat -
HY-111453
Velsecorat -
HY-13580
BudesonideGlucocorticoid Receptor Agonist -
HY-108243
AZD5423Glucocorticoid Receptor Modulator -
HY-B0415
Fluocinolone (Acetonide)Glucocorticoid Receptor Agonist -
HY-B0154
Fluticasone propionateGlucocorticoid Receptor Agonist -
HY-103662
GW-870086Glucocorticoid Receptor Agonist -
HY-B1616
Clobetasone butyrateGlucocorticoid -
HY-14864
MapracoratGlucocorticoid Receptor Agonist -
HY-111490
Desisobutyryl-ciclesonideGlucocorticoid Receptor Modulator -
HY-14234
Glucocorticoid receptor agonistGlucocorticoid Receptor Agonist -
HY-13693
Mometasone furoateGlucocorticoid Receptor Agonist
Publications Citing Use of MedChemExpress (MCE) AZD2906
More
Biological Activity
제품 설명
IC50 & Target
IC50: 2.2 nM (Glucocorticoid receptor, Human PBMC), 0.3 nM (Glucocorticoid receptor, Rat PBMC), 41.6 nM (Glucocorticoid receptor, Human whole blood), 7.5 nM (Glucocorticoid receptor, Rat whole blood)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ChaGo-K-1 | IC50 |
0.4 nM
Compound: 8s
|
Agonist activity at glucocorticoid receptor in human ChaGoK1 cells assessed as inhibition of AP1-mediated transcriptional activity by measuring reduction in PMA-stimulated TRE-LacZ activity after 24 hrs in presence of MUG by fluorometric assay
Agonist activity at glucocorticoid receptor in human ChaGoK1 cells assessed as inhibition of AP1-mediated transcriptional activity by measuring reduction in PMA-stimulated TRE-LacZ activity after 24 hrs in presence of MUG by fluorometric assay
|
[PMID: 27810243] |
| PBMC | IC50 |
0.29 nM
Compound: 8s
|
Antiinflammatory activity in Wistar rat PBMC assessed as inhibition of LPS-induced TNFalpha release preincubated for 45 mins followed by LPS addition after 18 hrs by ELISA
Antiinflammatory activity in Wistar rat PBMC assessed as inhibition of LPS-induced TNFalpha release preincubated for 45 mins followed by LPS addition after 18 hrs by ELISA
|
[PMID: 27810243] |
| PBMC | IC50 |
2.16 nM
Compound: 8s
|
Antiinflammatory activity in human primary PBMC assessed as inhibition of LPS-induced TNFalpha release preincubated for 45 mins followed by LPS addition after 18 hrs by ELISA
Antiinflammatory activity in human primary PBMC assessed as inhibition of LPS-induced TNFalpha release preincubated for 45 mins followed by LPS addition after 18 hrs by ELISA
|
[PMID: 27810243] |
In Vitro
AZD2906 is a selective glucocorticoid receptor (GR), with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AZD2906 (5, 25 mg/kg, p.o.) induces an accumulation of glycogen in the liver of rats, and exhibits cortical lymphocytic atrophy of a moderate to marked degree in the thymus of rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar Han rats (10 weeks old)[1]
-
Dosage:5, 25, 50 mg/kg
-
Administration:P.O. for 2 days
-
Result:Caused significant increase in micronucleated immature erythrocytes (MIE) at all doses after analysis of the standard 2000 IE.
Chemical Information
-
CAS No. 1034148-15-6
-
Appearance Solid
-
분자량 460.50
-
화학식 C26H25FN4O3
-
Color Light yellow to yellow
-
SMILES
FC1=CC=C(N2N=CC3=CC(O[C@@H]([C@@H](NC(C4CC4)=O)C)C5=CC=C(N=C5)OC)=CC=C23)C=C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Virol
2025 Feb 25;99(2):e0188624. PMID: 39817774
용액&용해도
In Vitro:
DMSO : 125 mg/mL (271.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1716 mL | 10.8578 mL | 21.7155 mL | 54.2888 mL |
| 5 mM | 0.4343 mL | 2.1716 mL | 4.3431 mL | 10.8578 mL | |
| 10 mM | 0.2172 mL | 1.0858 mL | 2.1716 mL | 5.4289 mL | |
| 15 mM | 0.1448 mL | 0.7239 mL | 1.4477 mL | 3.6193 mL | |
| 20 mM | 0.1086 mL | 0.5429 mL | 1.0858 mL | 2.7144 mL | |
| 25 mM | 0.0869 mL | 0.4343 mL | 0.8686 mL | 2.1716 mL | |
| 30 mM | 0.0724 mL | 0.3619 mL | 0.7239 mL | 1.8096 mL | |
| 40 mM | 0.0543 mL | 0.2714 mL | 0.5429 mL | 1.3572 mL | |
| 50 mM | 0.0434 mL | 0.2172 mL | 0.4343 mL | 1.0858 mL | |
| 60 mM | 0.0362 mL | 0.1810 mL | 0.3619 mL | 0.9048 mL | |
| 80 mM | 0.0271 mL | 0.1357 mL | 0.2714 mL | 0.6786 mL | |
| 100 mM | 0.0217 mL | 0.1086 mL | 0.2172 mL | 0.5429 mL |
AZD2906 Related Classifications
HY-113854 Related Classifications
Powered by Bioz